Elobixibat Completed Phase 2 Trials for Dyslipidemia Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01069783Study of A3309 in Patients With Dyslipidemia